Comment & Analysis

Even Sequenom bulls have had to admit that the past year has not been a good one for the lab ...

Hepatitis C is over. This is the underlying message of Gilead Sciences’ decision to cut its revenue ...

Two years into a disappointing launch, Merck & Co has decided that the US allergy market is no ...

MedTech

EventAnalyzer

Therapeutic Focus

Market Moving Events

EP Vantage Interviews